A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

NCT00769132 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Comparator: niacin + laropiprant
DRUG: Comparator: niacin
DRUG: Comparator: laropiprant
DRUG: Comparator: placebo

Sponsor

Merck Sharp & Dohme LLC